Main public logs
Combined display of all available logs of CAMIH. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 13:14, 4 November 2024 JDoerfler talk contribs deleted page Mücke, R (content was: "{{Author}}", and the only contributor was "Lbordihn" (talk))
- 13:12, 4 November 2024 JDoerfler talk contribs deleted page Tan, Y, Li, P (content was: "{{Author}}", and the only contributor was "EProba" (talk))
- 13:11, 4 November 2024 JDoerfler talk contribs deleted page Asfour, I; El Shazlyn, S; Fayek, MH; Hegab, HM; Raouf, S; Moussa, MAR (content was: "{{Author}}", and the only contributor was "Lbordihn" (talk))
- 15:12, 29 October 2024 JDoerfler talk contribs created page Project:About (Created page with "='''What is CAMIH?'''= CAMIH, short for Complementary and Alternative Medicine Insights Hub, is a database offering up-to-date evidence from randomized controlled trials on complementary approaches and methods for treating oncology patients. Each study has been meticulously reviewed and critically evaluated for methodological rigor using the ''Cochrane Risk of Bias Tool 2.0''. This approach ensures that the database not only provides a comprehensive collection of eviden...")
- 07:37, 29 October 2024 JDoerfler talk contribs deleted page Stratton, MS; Algotar, AM; Ranger-Moore, J; Stratton, SP; Slate, EH; Hsu, C; Thompson, PA; Clark, LC; Ahmann, FR (content was: "{{Author}}", and the only contributor was "Lbordihn" (talk))
- 10:15, 6 September 2024 JDoerfler talk contribs created page Okabayashi et al. (2020): L-Carnitine Improves Postoperative Liver Function in Hepatectomized Patients (Created page with "{{Reference |Reference=Publication: L-Carnitine Improves Postoperative Liver Function in Hepatectomized Patients }} {{Study Note}} =Brief summary= In this study, patients who had their liver removed due to liver cancer or biliary tract disease were included. The patients were randomly divided into 2 groups, with one group receiving carnitine for 2 weeks, while the other group received no additional intervention. After the surgery, a slightly shorter hospital stay was obs...")
- 09:38, 6 September 2024 JDoerfler talk contribs created page Publication: L-Carnitine Improves Postoperative Liver Function in Hepatectomized Patients (Created page with "{{Publication |Title=L-Carnitine Improves Postoperative Liver Function in Hepatectomized Patients; Journal |Topic=Carnitine |Author=Okabayashi T; Sui K; Mastumoto T; Iwata J; Morita S; Iiyama T; Shimada Y |Year=2020 |Journal=Journal of parenteral and enteral nutrition |DOI=https://doi.org/10.1002/jpen.1720 |Authors Abstract=Background and aims: The effect of perioperative treatment with L-carnitine in hepatectomized patients is unclear. The objectiveof the current study...")
- 08:12, 6 September 2024 JDoerfler talk contribs created page Hershman et al. (2018): Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L Carnitine (Created page with "{{Reference |Reference=Publication: Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L Carnitine }} {{Study Note}} =Brief summary= This study is a follow-up study of the 2013 study [Hershman et al. (2013): Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy], in which the data of the patients are reported afte...")
- 08:10, 6 September 2024 JDoerfler talk contribs created page Publication: Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L Carnitine (Created page with "{{Publication |Title=Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L Carnitine |Topic=Carnitine |Author=Hershman DL; Unger JM; Crew KD; Till C; Greenlee H; Minasian LM; Moinpour CM; Lew DL; Fehrenbacher L; Wade JL III; Wong SF; Fisch MJ; Henry NL; Albain KS |Year=2018 |Journal=Journal of the National Cancer |DOI=https://doi.org/10.1093/jnci/djx259 |Authors Abstract=Background: Chemotherapy-induced peripheral neuropathy (CI...")
- 12:28, 3 September 2024 JDoerfler talk contribs created page Zalat et al. (2020): Evaluation of the cardioprotective effects of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy (Created page with "{{Reference |Reference=Publication: Evaluation of the cardioprotective effects of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy }} {{Study Note |Study Note=? }} =Brief summary= This study evaluated data from 83 patients who were randomly divided into 3 arms: one arm received carnitine in addition to chemotherapy, another arm received silymarin (from milk thistle fruits) in addition to chemotherapy, and the third arm received...")
- 12:08, 3 September 2024 JDoerfler talk contribs created page Publication: Evaluation of the cardioprotective effects of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy (Created page with "{{Publication |Title=Evaluation of the cardioprotective effects of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy |Topic=Carnitine |Author=Zalat ZA; Elewa HA; Abdel-Latif M; Alm El-Din MA; Kohaf NA |Year=2020 |Journal=Journal of Bioscience and Applied Research |DOI=https://doi.org/10.21608/jbaar.2020.119755 |Authors Abstract=Aim: Anthracycline-induced cardiotoxicity is the most common constraint of its use in the treatment of...")
- 07:57, 3 September 2024 JDoerfler talk contribs created page Sun et al. (2016): A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy (Created page with "{{Reference |Reference=Publication: A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy }} {{Study Note |Study Note=? }} =Brief summary= This study shows the influence of acetyl-L-carnitine (ALC) on peripheral neuropathy as a result of chemotherapy. A total of 239 subjects participated in the study, of which 118 patients received ALC every day for 8 weeks (intervention arm) and...")
- 07:55, 3 September 2024 JDoerfler talk contribs created page Publication: A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy (Created page with "{{Publication |Title=A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy |Topic=Carnitine |Author=Sun Y; Shu Y; Liu B; Liu P; Wu C; Zheng R; Zhang X; Zhuang Z; Deng Y; Zheng L; Xu Q; Jiang B; Ouyang X; Gao J; Xu N; Li X; Jiang S; Liang C; Yao Y |Year=2016 |Journal=Experimental and therapeutic medicine |DOI=https://doi.org/10.3892/etm.2016.3871 |Authors Abstract=The present stud...")
- 13:37, 26 July 2024 JDoerfler talk contribs created page Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia (Created page with "{{Reference |Reference=Publication: Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia }} {{Study Note}} =Brief summary= This study was conducted with 332 patients and investigated the influence of carnitine, MPA/MA, EPA, thalidomide and a combination medication (carnitine + MPA/MA + EPA + thalidomide) on weight (fat mass and muscle mass) over 16 weeks in patients with acute weight loss due to cancer. The results...")
- 13:34, 26 July 2024 JDoerfler talk contribs created page Publication: Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia (Created page with "{{Publication |Title=Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia |Topic=Carnitine |Author=Mantovani, G; Macciò, A; Madeddu, C; Serpe, R; Massa, E; Dessì, M; Panzone, F; Contu, P |Year=2010 |Journal=The oncologist |DOI=https://doi.org/10.1634/theoncologist.2009-0153 |Authors Abstract=Purpose. A phase III, randomized study was carried out to establish the most effective and safest treatment to improve the...")
- 12:28, 23 July 2024 JDoerfler talk contribs created page Kraft et al. (2012): L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial (Created page with "{{Reference |Reference=Publication: L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial }} {{Study Note}} =Brief summary= This study included 72 patients with advanced pancreatic cancer who were randomly and fairly evenly divided into two groups. One group received the carnitine and the other group the placebo. The authors investigated the influence of carnitine on the weight caused by the disease, as well as the influence...")